RxDoctor Payments Data

Jorge Bustillo, MD

General Practice · Garrochales, PRNPI 1306032263

Payments from drug & device makers

$995in general payments, 2019–2025

Across 20 payments — averaging $49.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NS Pharma, Inc.$371
  • Smith+Nephew$163
  • AstraZeneca$123
  • Johnson & Johnson$79
  • E.r. Squibb & Sons, L.L.C.$75
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$62
  • plus $122 from 3 others

What the payments were for

  • Travel & lodging$222%
  • Food & beverage$97298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$995 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,912
Medicare patients
19
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban22$17,936
JanumetSitagliptin Phos/Metformin Hcl30$17,691
JardianceEmpagliflozin15$13,951
EliquisApixaban20$12,150
Breo ElliptaFluticasone/Vilanterol15$6,925
LantusInsulin Glargine,hum.Rec.Anlog32$6,053
SynthroidLevothyroxine Sodium68$5,467
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm15$2,122
Atorvastatin Calcium125$1,433
Gabapentin151$1,385
Famotidine216$1,382
Losartan Potassium117$1,232
Esomeprazole Magnesium43$1,211
Candesartan Cilexetil13$1,068
Levothyroxine Sodium73$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$79$17,93622 claims
Sanofi-aventis U.S. LLCLantus$15$6,05332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Garrochales

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →